VAN VUGT; Martine
Patent Applications and Registrations
Patent applications and USPTO patent grants for VAN VUGT; Martine.The latest application filed is for "antibodies against cd38 for treatment of multiple myeloma".
- VAN VUGT; Martine - Houten NL
| Patent | Date |
|---|---|
| Antibodies Against Cd38 For Treatment Of Multiple Myeloma App 20200283542 - DE WEERS; Michel ; et al. | 2020-09-10 |
| Combination Treatment Of Cd38-expressing Tumors App 20200114000 - VAN DE WINKEL; Jan ; et al. | 2020-04-16 |
| Antibodies Against Cd38 For Treatment Of Multiple Myeloma App 20160130362 - DE WEERS; Michel ; et al. | 2016-05-12 |
| Antibodies against CD38 for treatment of multiple myeloma Grant 9,187,565 - De Weers , et al. November 17, 2 | 2015-11-17 |
| Combination Treatment Of Cd38-expressing Tumors App 20150231235 - VAN DE WINKEL; Jan ; et al. | 2015-08-20 |
| Anti-OX40L antibodies Grant 9,102,733 - Endl , et al. August 11, 2 | 2015-08-11 |
| Combination treatment of CD38-expressing tumors Grant 9,040,050 - Van De Winkel , et al. May 26, 2 | 2015-05-26 |
| Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies Grant RE44,389 - Graus , et al. July 23, 2 | 2013-07-23 |
| Nucleic acid molecules encoding anti-P-selectin antibodies Grant RE44,359 - Graus , et al. July 9, 2 | 2013-07-09 |
| Anti-P-selectin antibodies Grant RE43,568 - Graus , et al. August 7, 2 | 2012-08-07 |
| Antibodies Against Cd38 For Treatment Of Multiple Myeloma App 20110099647 - DE WEERS; Michel ; et al. | 2011-04-28 |
| Antibodies Against Il-13 Receptor Alpha 1 And Uses Thereof App 20110086026 - Endl; Josef ; et al. | 2011-04-14 |
| Anti-ox40l Antibodies App 20110070239 - Endl; Joseph ; et al. | 2011-03-24 |
| Anti-OX40L antibodies Grant 7,868,141 - Endl , et al. January 11, 2 | 2011-01-11 |
| Antibodies against CD38 for treatment of multiple myeloma Grant 7,829,673 - De Weers , et al. November 9, 2 | 2010-11-09 |
| Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies Grant 7,824,684 - Graus , et al. November 2, 2 | 2010-11-02 |
| Antibodies against IL-13 receptor alpha1 and uses thereof Grant 7,807,158 - Endl , et al. October 5, 2 | 2010-10-05 |
| Methods Of Inhibiting The Binding Of P-selectin To Psgl-1 App 20100209423 - GRAUS; YVO ; et al. | 2010-08-19 |
| Nucleic acid molecules encoding anti-P-selectin antibodies Grant 7,754,867 - Graus , et al. July 13, 2 | 2010-07-13 |
| Anti-OX40L antibodies App 20100166740 - Endl; Joseph ; et al. | 2010-07-01 |
| Combination Treatment Of Cd38-expressing Tumors App 20100092489 - Van De Winkel; Jan ; et al. | 2010-04-15 |
| Anti-p-selectin Antibodies App 20090311779 - Graus; Yvo ; et al. | 2009-12-17 |
| Anti-P-selectin antibodies Grant 7,563,441 - Graus , et al. July 21, 2 | 2009-07-21 |
| Antibodies against CD38 for treatment of multiple myeloma App 20090076249 - De Weers; Michel ; et al. | 2009-03-19 |
| Anti-OX40L antibodies Grant 7,501,496 - Endl , et al. March 10, 2 | 2009-03-10 |
| Antibodies against IL-13 receptor alpha1 and uses thereof App 20060263356 - Endl; Josef ; et al. | 2006-11-23 |
| Anti-P-selectin antibodies App 20050226876 - Graus, Yvo ; et al. | 2005-10-13 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 